New findings show how damaged cells survive the cell cycle

As cells divide and replicate, important safety checkpoints are in place to ensure that most faulty cells with damaged DNA do not survive the cell cycle. In a new twist, CCR researchers discovered how some damaged cells use molecular inertia to drive past these safety checkpoints and continue through the cell cycle. Read more...

Lung Cancer, Stage IIIB (1)

Clinical trial studies drug combination for EGFR-mutated adenocarcinomas

Dec 3, 2020

Adults with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer that has transformed to small cell lung cancer or a neuroendocrine tumor may be eligible to participate in a clinical trial at the NIH Clinical Center. Anish Thomas, M.B.B.S., M.D., NIH Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, is leading a trial testing a drug combination to treat these kinds of tumors. Read more...

NC410 binds to tumor-associated ligands

Clinical trial evaluates therapy for advanced or metastatic solid tumors

Nov 30, 2020

Marijo Bilusic, M.D., Ph.D., Associate Research Physician in the Genitourinary Malignancies Branch, is leading NCI’s participation in a multicenter study for adults with advanced or metastatic solid (non-blood) tumors that have not responded to standard treatments. This phase 1 study will evaluate a therapy, NC410, for any serious side effects and determine the best dose that will achieve an antitumor response. Read more...

DNA

Embryonic stem cells have their own strategy for protecting chromosome ends

Nov 25, 2020

According to new research from CCR scientists, embryonic stem cells have a unique way of protecting their telomeres, the structures at the ends of chromosomes that shorten with every cell division. Understanding it could help explain how some cancer cells circumvent the growth limits imposed by the natural shortening of telomeres that occurs as we age. Read more...

Blood cell development

Clinical trial studies modified treatment regimen for patients with B-ALL

Nov 24, 2020

B-cell acute lymphoblastic leukemia (B-ALL) is a fast-growing type of blood cancer in which too many B cells multiply in the bone marrow and blood. Haneen Shalabi, D.O., Assistant Research Physician in the Pediatric Oncology Branch, is leading a study looking at a different way of preparing patients for bone marrow transplant after they have received treatment for B-ALL. Read more...

Crystals of IgG Antibodies

Clinical trial to test drug for cancer patients with weakened immune systems

Nov 16, 2020

Cancer survivors age 60 and older have weakened immune systems, often caused by cancer treatments. Investigators want to see if a drug, NT-I7, is able to boost the response to vaccines in patients who otherwise may not be able to respond. Read more...

photoimmunotherapy

Japan approves photoimmunotherapy for head and neck cancer

Nov 4, 2020

Promising clinical trials have led to the regulatory approval of the Bioblade® Laser System and Akalux® IV Infusion 250mg in Japan. This device and drug combination was developed under an investigational treatment platform based on a cancer therapy called photoimmunotherapy. Read more...

pancreatic cancer cells

Pancreatic Cancer Research

Nov 2, 2020

November is Pancreatic Cancer Awareness Month. We have many researchers, both in the basic and clinical disciplines, who are working on pancreatic cancer.  Learn more...

Lung cancer cells

Lung Cancer Research

Nov 2, 2020

November is Lung Cancer Awareness Month. Our research portfolio includes investigators making important discoveries in lung cancer research.  Read more...

stem cell transplant

New clinical trial studies stem cell transplant for primary immunodeficiency diseases

Oct 28, 2020

Dennis D. Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program is leading a study that uses new DNA technology that speeds up the process of screening for primary immunodeficiency diseases (PIDs) and finding an acceptable donor match for hematopoietic stem cell transplant (HSCT). Read more...

Prostate-specific membrane antigen

Clinical trial studies therapy for people with prostate or kidney cancer

Oct 22, 2020

James L. Gulley, M.D., Ph.D., Chief of the Genitourinary Malignancies Branch, is leading the National Cancer Institute’s participation in a clinical trial of an experimental drug called JNJ-63898081. The goal of this multicenter study is to find out if the drug is safe to use in humans and to determine the optimal dose for the second phase of the study. Read more...

Pages